Novozymes delivers 10% organic sales growth and an EBIT margin of 26% in the first half of the year, despite the volatile market environment. The company announces it adjusted its full-year organic sales outlook from 4-8% to now 6-8%.

“We deliver strong results for the first half of 2022 and growth is broad-based across the business. In fact, we deliver double-digit organic sales growth in four out of five business areas and in both developing and emerging markets. Our well-diversified portfolio and operational excellence prove the value our solutions generate for our customers. We are executing very well across our portfolio and markets, and in line with our strategic direction,” says Ester Baiget, President & CEO. In the first half of the 2022 financial year, Novozymes launched six new products, four of which in the second quarter, including “efficient yeast solutions in bioenergy and growth stimulators for broad acre crops in agriculture.”

Baiget also commented: “Following a strong first half of the year, we narrow our full-year outlook upwards to 6-8% organic sales growth, and we continue to expect solid margins and returns despite the significant pressure from input and logistic costs. This is a clear testament that our positioning and product portfolio are strong, and that we are able to drive our strategy forward balancing short-term execution with a clear long-term focus. We are ready to show the world the power of biotech.”

Highlights from our half year results: 10% organic sales growth, 26% EBIT-margin and double-digit growth in four of five business areas. In the clip, you can see how we are doing in markets across the world. In Latin America, we have delivered 19% organic sales growth. #biotech pic.twitter.com/DNlKoSuVZc

— Novozymes (@Novozymes) August 12, 2022

Photo: Novozymes Twitter